Related references
Note: Only part of the references are listed.Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101
Chun-Hao Chang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2023)
Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524
Jodie Green et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2023)
Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524
Sally J. Coggins et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2023)
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis
Wen Wen et al.
ANNALS OF MEDICINE (2022)
Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro
Sarah E. Cook et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2022)
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
A. Jayk Bernal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Yingjun Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Novel Nitrile Peptidomimetics for Treating COVID-19
C. S. Brian Chia
ACS Medicinal Chemistry Letters (2022)
Nirmatrelvir Plus Ritonavir: First Approval
Yvette N. Lamb
DRUGS (2022)
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
Jean G. Sathish et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2022)
Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors
Zhe Jiao et al.
JOURNAL OF VIROLOGY (2022)
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ronen Arbel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats
Sarah Cook et al.
VIRUSES-BASEL (2022)
Unlicensed Molnupiravir is an Effective Rescue Treatment Following Failure of Unlicensed GS-441524-like Therapy for Cats with Suspected Feline Infectious Peritonitis
Meagan Roy et al.
PATHOGENS (2022)
On the Calculation of TCID50 for Quantitation of Virus Infectivity
Chengfeng Lei et al.
VIROLOGICA SINICA (2021)
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
Wendy P. Painter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl et al.
NATURE (2021)
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White et al.
MBIO (2021)
β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
Shuntai Zhou et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
Koen Vandyck et al.
CURRENT OPINION IN VIROLOGY (2021)
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
Andreas Neubauer et al.
LEUKEMIA (2021)
COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series
Geraldine Luetic et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis
Sarah Jones et al.
ANIMALS (2021)
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis
Peter J. Dickinson et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
COVID-19 in teriflunomide-treated patients with multiple sclerosis
Amir Hadi Maghzi et al.
JOURNAL OF NEUROLOGY (2020)
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
Victoria C. Yan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
Maria Rosa Ciardi et al.
JOURNAL OF NEUROIMMUNOLOGY (2020)
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
Alessandro Gozzetti et al.
LEUKEMIA (2020)
Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
Niels C. Pedersen et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2019)
Cross-sectional quantitative RT-PCR study of feline coronavirus viremia and replication in peripheral blood of healthy shelter cats in Southern California
Eric J. Fish et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2018)
Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
Niels C. Pedersen et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2018)
The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies
B. G. Murphy et al.
VETERINARY MICROBIOLOGY (2018)
Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor
Yunjeong Kim et al.
PLOS PATHOGENS (2016)
Genotyping coronaviruses associated with feline infectious peritonitis
Catherine S. Lewis et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
An update on feline infectious peritonitis: Diagnostics and therapeutics
Niels C. Pedersen
VETERINARY JOURNAL (2014)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus
DD Addie et al.
VETERINARY RECORD (2000)